GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (STU:1UC) » Definitions » Price-to-Owner-Earnings

Cue Biopharma (STU:1UC) Price-to-Owner-Earnings : (As of May. 23, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cue Biopharma Price-to-Owner-Earnings?

As of today (2024-05-23), Cue Biopharma's share price is €1.71. Cue Biopharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Cue Biopharma's Price-to-Owner-Earnings or its related term are showing as below:


STU:1UC's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.67
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-23), Cue Biopharma's share price is €1.71. Cue Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.99. Therefore, Cue Biopharma's PE Ratio for today is At Loss.

As of today (2024-05-23), Cue Biopharma's share price is €1.71. Cue Biopharma's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.99. Therefore, Cue Biopharma's PE Ratio without NRI for today is At Loss.


Cue Biopharma Price-to-Owner-Earnings Historical Data

The historical data trend for Cue Biopharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Price-to-Owner-Earnings Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Cue Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cue Biopharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Cue Biopharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Price-to-Owner-Earnings falls into.



Cue Biopharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cue Biopharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.71/-0.86
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cue Biopharma  (STU:1UC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Cue Biopharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma (STU:1UC) Business Description

Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Cue Biopharma (STU:1UC) Headlines

No Headlines